2 hours ago
Sarepta Therapeutics (SRPT) Stock Climbs Following Positive siRNA Muscular Dystrophy Trial Results
Sarepta (SRPT) stock rises on positive Phase 1/2 siRNA trial data showing muscle delivery, biomarker activity, and safety in rare muscular dystrophy programs.
The post Sarepta Therapeutics (SRPT) Stock Climbs Following Positive siRNA Muscular Dystrophy Trial Results appeared first on Blockonomi.
Source: Blockonomi →Related News
- 50 minutes ago
TSMC (TSM), Broadcom (AVGO), and Micron (MU): Three AI Infrastructure Plays Beyo...
- 57 minutes ago
Intuitive Machines (LUNR) Stock Surges 14% on $180M NASA Moon Mission Deal
- 1 hour ago
Micron (MU) vs Western Digital (WDC): Which AI Infrastructure Stock Offers Bette...
- 1 hour ago
General Motors (GM) Stock Gets Bullish Upgrade as Analyst Sees Value After Recen...
- 1 hour ago
Meta Platforms (META) Unveils Ambitious $9 Trillion Market Cap Executive Compens...